Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 14/20 | 0.45 |
| ▸ | PPARD | Q03181 | 11/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18006416 | 0.93 | PPARD (0.48) | CYP2C9PPARGPPARAFFAR1PPARD | |
| SCHEMBL26070911 | 0.87 | CYP2C9 (0.47) | CYP2C9PPARGPPARAFFAR1PPARD | |
| SCHEMBL18006400 | 0.86 | SLC22A12 (0.36) | FFAR1PPARD | |
| SCHEMBL18005970 | 0.82 | NR4A2 (0.46) | PPARGMEN1KMT2A | |
| SCHEMBL18006346 | 0.81 | PPARA (0.47) | PPARGPPARALMNA | |
| SCHEMBL18006430 | 0.80 | SLC22A12 (0.39) | MEN1TSHRKMT2A | |
| SCHEMBL18006214 | 0.80 | PPARD (0.46) | PPARGPPARAFFAR1PPARD | |
| SCHEMBL18004812 | 0.80 | SMPD1 (0.47) | MEN1KMT2A | |
| SCHEMBL18006437 | 0.79 | CHEK1 (0.39) | TSHR | |
| SCHEMBL18006230 | 0.79 | PPARD (0.51) | PPARGPPARAFFAR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | CYP2C9 1517/4885PPARG 269/4885PPARA 284/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | CYP2C9 1517/4885PPARG 269/4885PPARA 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.